Phase i study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1531-1539

  Spano, Jean Philippe ^a   Moore, Malcolm J ^b   Pithavala, Yazdi K ^c   Ricart, Alejandro D ^c   Kim, Sinil ^c   Rixe, Olivier ^a,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c PFIZER INC   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Axitinib; Combination; Gemcitabine; Pancreatic cancer; Pharmacokinetics

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; ANTIBIOTIC AGENT; AXITINIB; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; ESOPHAGUS VARICES; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STEADY STATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS;

EID: 84866743413     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9697-2     Document Type: Article

References (31)

1. American Cancer Society. (2010) Cancer facts & figures 2010. http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113. pdf. Accessed July 14, 2010
2. Jemal A, Siegel R, Xu J, Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin caac.20073. doi:10.3322/caac.20073
3. American Cancer Society. (2007) Global cancer facts & figures 2007. http://www.cancer.org/downloads/STT/Global-Facts-and-Figures-2007-rev2.pdf. Accessed February 11, 2010
4. Saif MW. (2008) New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008. JOP 9:391-397
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
6. Berlin JD, Catalano P, Thomas JP, Kugler JW, HallerDG, BensonAB 3rd. (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 20:3270-3275. doi:10.1200/JCO.2002.11.149
7. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217. doi:10.1200/JCO.2006.09.0886
8. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167. doi:10.1038/sj.bjc. 6600446
9. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441-4447. doi:10.1200/JCO.2006.07.0201
10. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783. doi:10.1200/JCO.2004.12.082
11. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438. doi:10.1200/JCO.2004.10.112
12. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516. doi:10.1200/JCO.2005.06.023
13. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling- Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952. doi:10.1200/JCO.2005.05.1490
14. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966. doi:10.1200/JCO.2006.07.9525
15. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol. doi:10.1200/jco.2009.25.7550
16. Korc M. (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2:8. doi:10.1186/1476-4598-2-8
17. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. (2006) Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 106:1677-1684. doi:10.1002/cncr.21783
18. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib. (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283. doi:10.1158/1078-0432.CCR-08-0652
19. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483. doi:10.1200/JCO.2005.04.192
20. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. (2009) Efficacy and safety of axitinib in patients with advanced nonsmall- cell lung cancer: results from a phase II study. J Clin Oncol 27:3836-3841. doi:10.1200/JCO.2008.20.8355
21. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. (2007) Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975-984. doi:10.1016/S1470-2045(07)70285-1
22. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713. doi:10.1200/JCO.2007.15.9566
23. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181. doi:10.1016/S1053-4296(03)00031-6
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92:205-216. doi:10.1093/jnci/92.3.205
25. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82. doi:10.1186/1471-2407-8-82
26. Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A. (2007) Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 60:295-303. doi:10.1007/s00280-006-0389-0
27. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, PithavalaY, Bycott P, Trask P, LiauK, Ricart AD, Kim S, Rixe O. (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:2101-2108. doi:10.1016/S0140-6736(08)60661-3
28. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al. (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
29. Yilmaz B, Kadioglu YY, Aksoy Y. (2004) Investigation of the pharmacokinetics of gemcitabine and 2', 2'-difluorodeoxyuridine in human plasma by liquid chromatography. Anal Biochem 332:234-237. doi:10.1016/j.ab.2004.05.059
30. Delaloge S, Llombart A, Di Palma M, Tourani JM, Turpin F, Ni L, Forgue ST, Le Chevalier T. (2004) Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study. Am J Clin Oncol 27:289-293
31. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12:256-262. doi:10.1016/S1470-2045(11)70004-3